Updated on 4 August 2026
Scaling Fast DNA Diagnostics in Oncology: OaCP Pre-Series A Funding Round ($2.7M) & Regional Expansion
CEO at OACP IE LTD
Italy
About
Looking for: Institutional & strategic investors, venture capital, and regional healthcare partners.
OaCP IE LTD is raising a $2.7M Pre-Series A round to expand its IVDR-approved, IP-protected fast diagnostic reagent technology across EMEA, the Middle East, and Asia. Project Highlights:
Proven Impact:
Reagents compress cancer FISH test turnaround from days to 2 hours with >98% sensitivity, saving up to 50% in lab costs.
Regulatory & IP Moat: Granted patents in EU, US, China, and India; ISO 13485 certified; CE-IVDR compliant; MISA licensed in KSA. Traction: >$1M revenue achieved across EU and Japan; active commercial engagement with Roche and University of Michigan.
Scope of Project: Funding will accelerate market entry in Asia and Saudi Arabia, the FDA 510(k) clearance and the rollout of our AICP AI-driven quality control suite,
Project Location
- Ireland
Project Website
https://www.oncology-and-cytogenetic-products.com/
Project Format
- Private Project
Go Global Project
- Yes
ESG (Environmental, Social, and Governance)
- Yes
Project Stage
- Operations
Main Project Sector
- Technology
Technology
- Bio-Tech
- Health Technology
- Medical Technology
Total Project Value
- 10,000,001 to 25,000,000 USD
Investment Capital Required
- 2,500,001 to 5,000,000 USD
Interested Format of Cooperation
- Convertible Loan
- Direct Equity Investment
- M&A / Strategic Acquisition Opportunity
Preferred Financing Model
- Equity
- Open for negotiation
Type(s) of Last Financing Round of the project (if Applicable)
- Convertible Loan
Total amount raised (USD)
500000
Return on Investment
130
Main Service(s) Required
- Financial Services
Financial Services
- Institutional Investment
Organisation
Ireland
Similar opportunities
Project
Endosopy AI | Eliminating blind spots | Global Distribution
- No
- Yes
- Technology
- Operations
- Private Project
- Convertible Loan
- Convertible Loan
- Medical Technology
- 500,000 USD or Below
- Direct Equity Investment
- Information Technology Services
Saurabh Jejurikar
CEO at Endovision
China (Hong Kong)
Project
Paradigm-shifting healthtech solution dealing with the deadliest health condition worldwide
- Yes
- Yes
- Equity
- Bio-Tech
- Technology
- Private Project
- Convertible Loan
- Health Technology
- Medical Technology
- Financial Services
- Open for negotiation
- Professional Services
- Direct Equity Investment
- 2,500,001 to 5,000,000 USD
- 25,000,001 to 50,000,000 USD
- Public / Alternative Financing
- Investment / Financing Discussion
san pun
CEO at AiMorphous Healthtech
China (Hong Kong)
Project
Novel MET Amplification-Targeting Small-Molecule Kinase Inhibitor (HJ-462 BIC)
- Yes
- Yes
- Debt
- Equity
- Bio-Tech
- Technology
- Joint Venture
- Private Project
- Health Technology
- Convertible Loan
- Equity (private)
- Financial Services
- Direct Equity Investment
- 5,000,001 to 7,500,000 USD
- 1,000,001 to 2,500,000 USD
- Investment / Financing Discussion
- M&A / Strategic Acquisition Opportunity
Haiyang Wang
CEO at Shanghai Haiju Biotechnology Co., Ltd.
China